European Commission's Lalis promises changes to address regulatory fragmentation
This article was originally published in Clinica
Creating "a more stable and predictable regulatory framework" for medical devices is a key priority for Georgette Lalis, director at the Commission's Directorate General Enterprise and Industry, with oversight for medical devices and pharmaceuticals. To achieve this, Mrs Lalis and her team are looking at a range of stricter legal instruments than have historically been used for medical devices to ensure a more homogeneous implementation. Regular use of comitology to implement decisions and the possible reinforcement of the "meddev" guidance documents are now on the agenda for the woman who is on charge of regulations for five categories of consumer goods within Directorate F.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.